Cereno Scientific ,a company developing innovative treatments for common and rare cardiovascular disease, today announced that an abstract on preclinical drug candidate CS585 has been. | May 15, 2023
Cereno Scientific today announced that an abstract on the preclinical drug candidate CS585 has been accepted as an oral presentation at the scientific conference Vascular Discovery. | April 21, 2023